AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Bardy diagnostics logo11/23/2023 By joining Hillrom, we will broaden our footprint globally with the goal of providing greater patient value and more confident physician diagnoses." "Our team coupled advanced diagnostics with comfort and ease-of-use for the patient, and simple implementation for clinicians. Bardy, M.D., electrophysiologist, founder and chief medical officer of Bardy Diagnostics. "We set out to elevate ECG monitoring through an entirely new approach to signal processing, ECG reader training and report analysis tools and format, which allow for precise diagnoses of both common and abstruse arrhythmias," said Gust H. BardyDx, with annualized revenue of approximately $30 million, provides a differentiated, wearable bio-sensing technology, the Carnation Ambulatory Monitor (or CAM™ patch), that is engineered for patient-comfort, superior P-wave clarity, exceptional diagnostic yield and superior clinical accuracy. The acquisition of BardyDx complements Hillrom's current cardiology portfolio of cardiac stress exercise, Holter and resting electrocardiography (ECG) devices. We look forward to welcoming the 230 employees who will join us in our mission of enhancing outcomes for patients and their caregivers." "BardyDx brings a talented team with significant commercial, clinical and scientific expertise, and dedicated independent diagnostic testing facilities. "This acquisition provides Hillrom with a highly strategic and differentiated diagnostic cardiology platform aligned with our vision of Advancing Connected Care™, as well as an attractive recurring, high-growth revenue stream and gross margin profile," said Hillrom President and CEO John Groetelaars. Hillrom is also acquiring net operating losses valued at more than $20 million that are expected to result in future tax benefits. Under the terms of the agreement, Hillrom will purchase BardyDx for a cash consideration of $375 million and future potential payments based on the achievement of certain commercial milestones. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies. 19, 2021 /PRNewswire/ - Hillrom (NYSE: HRC) today announced it has reached a definitive agreement to acquire Bardy Diagnostics, Inc. Hillrom Advances Digital Health Offering With Expansion Into Attractive Ambulatory Cardiac Monitoring SegmentĬHICAGO, Jan.
0 Comments
Read More
Leave a Reply. |